Business Features

Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

The bio/pharmaceutical industry is struggling with the challenge of staffing and training.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.

Start-ups are plagued with common issues that dramatically decrease their odds of achieving investor funding.

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

The debate surrounding drug pricing changes rages on.

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

What factors do CDMOs consider vital to their success?

COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.

Context surrounding the Inflation Reduction Act is necessary for a comprehensive understanding of the global biopharma market.

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

What can we take away from Pfifzer's acquisition of Seagen?

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.